Intended Audience: All neonatal nurses NCC Category Codes: NIC 3, NNP 4
Objectives: Upon completion, learners will be able to:
Identify the risk factors for PPHN.
Describe the pathophysiology of PPHN.
Discuss the pulmonary vasodilators used in the management of PPHN.
Purpose of this CE Activity: The purpose of this activity is to describe the pathophysiology of persistent pulmonary hypertension of the newborn and the pharmacotherapy used to treat this disease state.
Requirements for Completion: The following requirements are necessary for successful completion of this CNE activity.
Access to a computer with an Internet connection
Pass the posttest with a score of 80%
Complete and submit the evaluation for this CNE activity
Accreditation Provider, Academy of Neonatal Nursing, approved by the California Board of Registered Nursing, Provider #CEP 6261; and Florida Board of Nursing, Provider #FBN 3218, content code 2505.
The Academy of Neonatal Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Release Date: May/June 2017 Review Date: June 2020 Expiration Date: June 30, 2022
Disclosures:
This CNE activity has been reviewed by the Lead Nurse Planner. It has been determined that the material presented here shows no bias.
The content of this CNE activity has been developed by the planning committee and has been reviewed by the Lead Nurse Planner.
Disclaimer: The Academy of Neonatal Nursing assumes no responsibility or liability for the content presented. Care of the infant should always be individualized and no one source relied upon for information regarding aspects of care. Accredited status does not imply endorsement by ANN, ANA, or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity.
